Continuation rate of S-1 administration.
toxicity
The treatment completion rate based on an RDI of 70% or more for 6 months in Arm A was greater than 40% and it did not exceed that of Arm B by more than 15%, indicating that both Arm A and Arm B were feasible. To determine which is more suitable as S-1 therapy in future Phase III trials, the comparison between the two groups should not be performed with the treatment completion rate alone, but rather with toxicity, quality of life, convenience, cost, treatment completion rate after 6 months, RFS, and OS.